Related references
Note: Only part of the references are listed.Overcoming TGFβ-mediated immune evasion in cancer
Daniele V. F. Tauriello et al.
NATURE REVIEWS CANCER (2022)
TGFβ biology in cancer progression and immunotherapy
Rik Derynck et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2021)
Spatial immunophenotypes predict response to anti-PD1 treatment and capture distinct paths of T cell evasion in triple negative breast cancer
Dora Hammerl et al.
NATURE COMMUNICATIONS (2021)
Epithelial plasticity, epithelial-mesenchymal transition, and the TGF-β family
Yoko Katsuno et al.
DEVELOPMENTAL CELL (2021)
Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial
Robert L. Ferris et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
TGF-β1-A truly transforming growth factor in fibrosis and immunity
Monika Lodyga et al.
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY (2020)
TGF-beta: a master immune regulator
Christopher Larson et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2020)
Clinical development of therapies targeting TGF beta: current knowledge and future perspectives
D. Ciardiello et al.
ANNALS OF ONCOLOGY (2020)
Clinical Challenges of Immune Checkpoint Inhibitors
Maria de Miguel et al.
CANCER CELL (2020)
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer
T. Andre et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
α-PD-1 therapy elevates Treg/Th balance and increases tumor cell pSmad3 that are both targeted by -TGF antibody to promote durable rejection and immunity in squamous cell carcinomas
E. Dodagatta-Marri et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Impact of hypoxic tumor microenvironment and tumor cell plasticity on the expression of immune checkpoints
Audrey Lequeux et al.
CANCER LETTERS (2019)
Transforming Growth Factor-β Signaling in Immunity and Cancer
Eduard Batlle et al.
IMMUNITY (2019)
HPV-positive status associated with inflamed immune microenvironment and improved response to anti-PD-1 therapy in head and neck squamous cell carcinoma
Jian Wang et al.
SCIENTIFIC REPORTS (2019)
Transforming growth factor-β signaling: Tumorigenesis and targeting for cancer therapy
Amirhossein Ahmadi et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2019)
T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028
Patrick A. Ott et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
Robert M. Samstein et al.
NATURE GENETICS (2019)
New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer
Anushka Dongre et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2019)
Immune checkpoint blockade therapy
Thomas Wieder et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2018)
TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis
Daniele V. F. Tauriello et al.
NATURE (2018)
Contextual determinants of TGFβ action in development, immunity and cancer
Charles J. David et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2018)
Cancer immunotherapy using checkpoint blockade
Antoni Ribas et al.
SCIENCE (2018)
Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β
Yan Lan et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
TGF-β in T Cell Biology: Implications for Cancer Immunotherapy
Amina Dahmani et al.
CANCERS (2018)
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Sanjeev Mariathasan et al.
NATURE (2018)
IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade
Mark Ayers et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
Arjun V. Balar et al.
LANCET (2017)
Cancer Neoantigens and Applications for Immunotherapy
Alexis Desrichard et al.
CLINICAL CANCER RESEARCH (2016)
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
Jonathan E. Rosenberg et al.
LANCET (2016)
Predictive biomarkers for checkpoint inhibitor-based immunotherapy
Geoffrey T. Gibney et al.
LANCET ONCOLOGY (2016)
Density of immunogenic antigens does not explain the presence or absence of the T-cell-inflamed tumor microenvironment in melanoma
Stefani Spranger et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity
Michael S. Rooney et al.
CELL (2015)
Integrative Analysis of Head and Neck Cancer Identifies Two Biologically Distinct HPV and Three Non-HPV Subtypes
Michaela K. Keck et al.
CLINICAL CANCER RESEARCH (2015)
Molecular mechanisms of epithelial-mesenchymal transition
Samy Lamouille et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2014)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Latent TGF-β structure and activation
Minlong Shi et al.
NATURE (2011)
GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers
Craig H. Mermel et al.
GENOME BIOLOGY (2011)
TGF-β-induced epithelial to mesenchymal transition
Jian Xu et al.
CELL RESEARCH (2009)
Myofibroblast contraction activates latent TGF-β1 from the extracellular matrix
Pierre-Jean Wipff et al.
JOURNAL OF CELL BIOLOGY (2007)
TGFβ-SMAD signal transduction:: molecular specificity and functional flexibility
Bernhard Schmierer et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2007)
Distinct regulation of gene expression in human endothelial cells by TGF-beta and its receptors
XP Wu et al.
MICROVASCULAR RESEARCH (2006)
Integrin αvβ6-mediated activation of latent TGF-β requires the latent TGF-β binding protein-1
JP Annes et al.
JOURNAL OF CELL BIOLOGY (2004)